FEDERAL Health Minister Greg Hunt has announced a new agreement with Pfizer Australia for the supply of 500,000 courses of the company's investigational oral antiviral candidate medication for COVID-19.
Subject to regulatory approval by the Therapeutic Goods Administration, PF-07321332 in combination with ritonavir, is said to be the first orally administered investigational candidate to be evaluated in clinical trials that is specifically designed to combat COVID-19.
PF-07321332 is a protease inhibitor which is designed to block the activity of the main SARS-CoV-2 protease, an enzyme essential for viral replication.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 21
